[Newsmp] The Ministry of Food and Drug Safety approved the orphan drug Tecvayli (ingredient: teclistamab) for the treatment of multiple myeloma on July 26.
Multiple myeloma is a type of blood cancer that occurs when plasma cells, a type of white blood cell that helps the immune system, abnormally divide and multiply in the bone marrow.
As a monoclonal antibody, Tecvayli is used in adult patients with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Tecvayli specifically targets and binds to BCMA (B-cell maturation antigen) antigens on cancer cells. It binds to CD3 proteins present on T cells, activating the immune system to effectively eliminate cancer cells.
